Cell-Free DNA (cfDNA) Kits Market Report 2026

Cell-Free DNA (cfDNA) Kits Market Overview

• Cell-Free DNA (cfDNA) Kits market size has reached to $1.8 billion in 2025 • Expected to grow to $3.2 billion in 2030 at a compound annual growth rate (CAGR) of 12.2% • Growth Driver: Rising Prevalence Of Genetic Disorders Driving The Growth Of The Market Due To Increasing Demand For Early And Non-Invasive Diagnostics • Market Trend: Advancements In Transplant Monitoring Through Innovative cfDNA Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cell-Free DNA (cfDNA) Kits Market?

Cell-free DNA (cfDNA) kits are specialized laboratory tools designed to isolate and analyze fragmented deoxyribonucleic acid (DNA) circulating freely in blood or other body fluids. These kits enable non-invasive genetic testing by providing high-quality DNA for applications such as prenatal screening, cancer diagnostics, and transplant monitoring. They streamline sample preparation and ensure accuracy in downstream molecular analysis. The main types of products in the cell-free DNA (cfDNA) kits market are plasma cell-free DNA (cfDNA) kits, serum cell-free DNA (cfDNA) kits, urine cell-free DNA (cfDNA) kits, and others. Plasma cell-free DNA (cfDNA) kits refer to specialized kits designed to isolate and analyze cell-free DNA fragments circulating in plasma, which is the liquid component of blood. The technologies comprise next-generation sequencing (NGS), polymerase chain reaction (PCR), microarray technology, and digital polymerase chain reaction (PCR). The key applications are cancer diagnostics, prenatal testing, transplant rejection monitoring, and non-invasive disease detection. The distribution channels include direct sales, retail pharmacies, online sales, and distributors, while the end users are hospitals, research laboratories, diagnostic laboratories, and academic institutions.

What Is The Cell-Free DNA (cfDNA) Kits Market Growth Forecast?

The cell-free dna (cfdna) kits market size is expected to see rapid growth in the next few years. It will grow to $3.2 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to technological innovations in cfDNA kits, increasing focus on non-invasive diagnostics, AI integration in analysis, expansion of molecular testing in emerging markets, increased R&D in cancer biomarkers. Major trends in the forecast period include high-sensitivity dna isolation, automation of sample preparation, integration with ngs platforms, rapid dna extraction, standardized cfdna kits.

Global Cell-Free DNA (cfDNA) Kits Market Segmentation

1) By Product Type: Plasma Cell-Free DNA (Cfdna) Kits, Serum Cell-Free DNA (Cfdna) Kits, Urine Cell-Free DNA (Cfdna) Kits, Other Product Types 2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray Technology, Digital Polymerase Chain Reaction(PCR) 3) By Application: Cancer Diagnostics, Prenatal Testing, Transplant Rejection Monitoring, Non-Invasive Disease Detection 4) By Distribution Channel: Direct Sales, Retail Pharmacies, Online Sales, Distributors 5) By End User: Hospitals, Research Laboratories, Diagnostic Laboratories, Academic Institutions Subsegments: 1) By Plasma Cell-Free DNA Kits: Single-Stranded DNA Kits, Double-Stranded DNA Kits, High-Sensitivity DNA Kits, Rapid Extraction DNA Kits 2) By Serum Cell-Free DNA Kits: Low-Volume DNA Kits, High-Yield DNA Kits, Automated DNA Kits, Manual Extraction DNA Kits 3) By Urine Cell-Free DNA Kits: Early Detection DNA Kits, Concentration DNA Kits, High-Purity DNA Kits, Long-Term Stability DNA Kits 4) By Other Product Types: Saliva DNA Kits, Cerebrospinal Fluid DNA Kits, Amniotic Fluid DNA Kits, Tissue-Derived DNA Kits

What Is The Driver Of The Cell-Free DNA (cfDNA) Kits Market?

The rising prevalence of genetic disorders is expected to boost the growth of the cell-free DNA (cfDNA) kits market in the coming years. Genetic disorders are medical conditions caused by changes in a person’s DNA, which may result from mutations in one gene, multiple genes, or chromosomal abnormalities. The rising prevalence of genetic disorders is driven by lifestyle changes and environmental factors such as pollution and unhealthy diets, which can cause genetic mutations or aggravate inherited conditions. Cell-free DNA (cfDNA) kits support early and non-invasive detection of genetic abnormalities by analyzing DNA fragments from blood or other body fluids, enabling faster diagnosis and helping healthcare providers make timely and accurate treatment decisions. For instance, in November 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, about 1 in every 33 newborns in the US is born with a birth defect, many linked to genetic causes. Therefore, the rising prevalence of genetic disorders is driving the growth of the cell-free DNA (cfDNA) kits industry.

Key Players In The Global Cell-Free DNA (cfDNA) Kits Market

Major companies operating in the cell-free dna (cfdna) kits market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V, Natera Inc., Myriad Genetics Inc., Guardant Health Inc., Bioneer Corporation, Streck Inc., Freenome Holdings Inc., GRAIL Inc., Zymo Research Corporation, Geneseeq Technology Inc, Covaris LLC, Active Motif Inc., Norgen Biotek Corp, AMSBIO LLC, EpiGentek Group Inc., Paragon Genomics Inc., Suzhou Beaver Biomedical Engineering.

Global Cell-Free DNA (cfDNA) Kits Market Trends and Insights

Major companies operating in the cell-free DNA (cfDNA) kits market are focusing on developing innovative products with digital polymerase chain reaction (PCR)-based absolute quantification to enhance the sensitivity and precision of cfDNA analysis. Digital PCR-based absolute quantification enables highly accurate detection of low-frequency genetic variants with improved consistency, supporting critical applications in cancer diagnostics, prenatal testing, and transplant rejection monitoring. For instance, in June 2024, Omixon, a Hungary-based molecular diagnostics company, launched HoloGRAFT ONE, a research-use-only kit designed for post-transplant monitoring of donor-derived cell-free DNA (dd-cfDNA). The kit leverages proprietary genetic markers and digital PCR to distinguish donor DNA from the patient’s DNA, measuring both absolute and relative amounts of dd-cfDNA through copy-number variants. This innovative test aims to enable early detection of transplant rejection, enhance patient monitoring, and support personalized post-transplant care by providing clinicians with precise, actionable cfDNA measurements.

What Are Latest Mergers And Acquisitions In The Cell-Free DNA (cfDNA) Kits Market?

In November 2025, Natera Inc., a US-based genetic testing and diagnostics company, acquired certain reproductive health assets from Invitae for an undisclosed amount. With this acquisition, Natera aims to expand its molecular diagnostic portfolio and grow its customer base by integrating Invitae’s non-invasive prenatal screening and carrier screening business, enabling broader access to personalized genetic testing and diagnostics. Invitae Corporation is a US-based medical genetics company specializing in cell-free DNA (cfDNA) testing kits for non-invasive prenatal testing and oncology applications.

Regional Outlook

North America was the largest region in the cell-free DNA (cfDNA) kits market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Cell-Free DNA (cfDNA) Kits Market?

The cell-free DNA (cfDNA) kits market consists of revenues earned by entities by providing services such as purification services, bulk services, quality control (QC) services, data integration services, and custom biomarker discovery services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell-free DNA (cfDNA) kits market also includes sales of plasma separation consumables, liquid biopsy assay kits, serum preparation kits, concentration kits, and bisulfite conversion and methylation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.